Entering text into the input field will update the search result below

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2020 Results - Earnings Call Transcript

May 05, 2020 12:51 AM ETCorcept Therapeutics Incorporated (CORT)
SA Transcripts profile picture
SA Transcripts

Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2020 Earnings Conference Call May 4, 2020 5:00 PM ET

Company Participants

Joseph Belanoff - President and Chief Executive Officer

Charlie Robb - Chief Financial Officer

Conference Call Participants

Charles Duncan - Cantor Fitzgerald

Tazeen Ahmad - Bank of America

Matt Kaplan - Ladenburg Thalmann

Chris Howerton - Jefferies

Swayampakula Ramakanth - H.C. Wainwrigh

Alan Leong - BioWatch News


Good day, everyone and welcome to the Corcept Therapeutics Conference Call. Today's conference is being recorded. [Operator Instructions]

At this time, I'd like to turn things over to Mr. Charlie Robb, Chief Financial Officer. Please go ahead, sir.

Charlie Robb

Good afternoon. Today, we issued a press release announcing our financial results for the first quarter and providing a corporate update. A copy is available at corcept.com. Complete results will be available when we file our Form 10-Q with the SEC.

Today's call is being recorded. A replay will be available through May 18 at 888-203-1112 in the United States and 719-457-0820 internationally. The pass code will be 2827359.

Statements during this call, other than statements of historical fact, are forward-looking statements based on our plans and expectations that are necessarily subject to risks and uncertainties, which might cause actual results to differ materially from those such statements expressed or imply. These risks and uncertainties include, but are not limited to, our ability to operate our business and achieve our goal during the COVID-19 pandemic and thereafter; generate sufficient revenue and cash reserves to fund our commercial operations and development programs; the availability of competing treatments, including generic versions of Korlym, the initiation or outcome of litigation, our ability to obtain acceptable prices at or adequate insurance coverage and reimbursement for Korlym, and risks related to the development of our product candidates, including their clinical attributes, regulatory approvals, mandates, oversight and other requirements, and the impact of the COVID-19 pandemic on our

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About CORT

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on CORT

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.